New insight and therapeutic strategies in cardiovascular disease and focus on endothelial target: endothelin-1 and angina.
This paper aims to demonstrate that there is currently sufficient evidence to suggest that endothelin-1 (ET-1) may play a role in angina and be associated with myocardial ischaemia. In order to demonstrate the potential role of ET-1 in angina, this paper examines three main factors: (i) that endothelin-1 can cause the pathophysiological states associated with myocardial ischaemia and angina; (ii) that ET-1 is over-expressed in humans and in animal models of myocardial ischaemia, which is associated with angina; and (iii) that modification of the ET-1 system is associated with an improvement in myocardial ischaemia and angina.
Lerman
A
A
Department of Internal Medicine, Mayo Clinic Rochester, Minnesota 55905, USA. lerman.amir@mayo.edu
D000787:Angina Pectoris / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology*; D000818:Animals; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology*; D006152:Cyclic GMP / Q000378:metabolism; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1 / Q000037:antagonists & inhibitors / Q000502:physiology*; D004730:Endothelium, Vascular / Q000187:drug effects / Q000503:physiopathology; D006801:Humans; D017202:Myocardial Ischemia / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology*
D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1; D006152:Cyclic GMP